Back to search results

Feasibility and Acceptability of Sentinel for Hematopoietic Stem Cell Transplant Patients

This study is testing a new approach called Sentinel, which is a primary palliative care (PC) intervention. Palliative care focuses on providing comfort and support to improve your quality of life. Sentinel aims to train transplant clinicians (like nurse practitioners) to deliver PC to patients undergoing hematopoietic stem cell transplantation (HCT) for blood cancers. The goal is to see if Sentinel is practical to use and if patients find it helpful. You might be able to join if you are 18 or older and are having an HCT at MGH. The study will look at how practical Sentinel is for up to 90 days. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 40 participants. It is designed to assess the feasibility and acceptability of the Sentinel intervention.
What's involved
Enrolled participants will receive the Sentinel intervention before and during their hospitalization for HCT. A transplant clinician will conduct a focused PC visit prior to HCT.
Compensation
Not stated in the trial record.
Follow-up
Feasibility will be measured up to Day 90 after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06676852

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~40 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:Primary palliative care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility
Measured over Up to Day 90

Conditions

Hematopoietic Cell Transplant
Hematologic Malignancy

Explore related trials

Hematopoietic Cell TransplantationMalignant neoplasm of lymphoid, hematopoietic and/or related tissue

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Richard A Newcomb, MD
[email protected]
617-996-7584
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Undergoing autologous or allogeneic HCT at MGH

Exclusion

Prior receipt of inpatient specialty palliative care on two prior admissions in the past 6 months.
Significant uncontrolled psychiatric disorders (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the primary oncologist believes prohibits informed consent or ability to participate in study procedures
Inability to comprehend English as this is a preliminary/pilot study

What this trial measures

  • FeasibilityUp to Day 90

    We will assess feasibility of Sentinel based on the proportion of eligible patients who enroll and the proportion of enrolled patients retained. Sentinel will be deemed feasible if at least 60% of eligible patients are enrolled in the study and patient retention through study procedures is at least 80%, commonly utilized metrics in PC trials